Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624
This study is recruiting at 33 US sites in 21 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS in androgen receptor ligand binding domain (AR LBD) mutation-negative and -positive participants.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer Metastatic
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Merck Sharp & Dohme LLC
- Last updated on ClinicalTrials.gov
- October 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Stanford Cancer Center ( Site 0036) · Palo Alto, CA
- Kaiser Permanente Riverside Medical Center ( Site 0099) · Riverside, CA
Colorado · 3
- Anschutz Cancer Pavilion ( Site 0046) · Aurora, CO
- University of Colorado Health - Highlands Ranch Hospital ( Site 0111) · Highlands Ranch, CO
- University of Colorado Health - Lone Tree Medical Center ( Site 0112) · Lone Tree, CO
Connecticut · 1
- Yale-New Haven Hospital-Yale Cancer Center ( Site 0064) · New Haven, CT
Florida · 1
- University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0051) · Miami, FL
Illinois · 2
- University of Chicago Medical Center ( Site 0045) · Chicago, IL
- University of Illinois at Chicago ( Site 0105) · Chicago, IL
Maryland · 2
- Baltimore Veterans Affairs Medical Center ( Site 0069) · Baltimore, MD
- Greenebaum Comprehensive Cancer Center ( Site 0049) · Baltimore, MD
Minnesota · 2
- Avera Cancer Institute - Marshall ( Site 0122) · Marshall, MN
- M Health Fairview Clinics and Surgery Center ( Site 0019) · Minneapolis, MN
Mississippi · 1
- Hattiesburg Clinic Hematology/Oncology ( Site 0120) · Hattiesburg, MS
Missouri · 1
- Washington University School of Medicine-Internal Medicine/Oncology ( Site 0062) · St Louis, MO
Nebraska · 1
- University Of Nebraska Medical Center-Oncology/Hematology ( Site 0095) · Omaha, NE
Nevada · 1
- Comprehensive Cancer Centers of Nevada ( Site 0010) · Las Vegas, NV
New Jersey · 1
- Atlantic Health System Morristown Medical Center ( Site 0115) · Morristown, NJ
New York · 1
- James J. Peters VA Medical Center ( Site 0088) · The Bronx, NY
Ohio · 1
- University Hospitals Cleveland Medical Center ( Site 0043) · Cleveland, OH
Oregon · 1
- VA Portland Health Care System ( Site 0058) · Portland, OR
South Dakota · 5
- Avera Cancer Institute - Aberdeen ( Site 0123) · Aberdeen, SD
- Avera Cancer Institute - Mitchell ( Site 0121) · Mitchell, SD
- Avera Cancer Institute - Pierre ( Site 0118) · Pierre, SD
- Avera Cancer Institute- Research ( Site 0094) · Sioux Falls, SD
- Avera Cancer Institute - Yankton ( Site 0117) · Yankton, SD
Tennessee · 1
- SCRI Oncology Partners ( Site 7000) · Nashville, TN
Texas · 2
- Texas Oncology - Central/South Texas ( Site 8003) · Austin, TX
- Texas Oncology - Gulf Coast ( Site 8002) · Houston, TX
Virginia · 2
- University of Virginia Health System ( Site 0054) · Charlottesville, VA
- Blue Ridge Cancer Care ( Site 0004) · Roanoke, VA
Washington · 1
- Fred Hutchinson Cancer Center ( Site 0013) · Seattle, WA
Wisconsin · 1
- Medical College of Wisconsin ( Site 0020) · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.